Ma, Li
Zhang, Jiancheng
Fujita, Yuko
Qu, Youge
Shan, Jiajing
Wan, Xiayun
Wang, Xingming
Ishima, Tamaki
Kobayashi, Kenta
Wang, Long
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20dm0107119)
MEXT | Japan Society for the Promotion of Science (21H02846)
National Natural Science Foundation of China (81772044)
Article History
Received: 28 October 2021
Revised: 4 January 2022
Accepted: 12 January 2022
First Online: 21 January 2022
Competing interests
: KH is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH has also received speakers’ honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm, and Perception Neuroscience. Other authors declare no conflict of interest.